FSHD researchers report in Cell that DBE-T may be a valid therapeutic target for FSHD More May 7th joint press release from San Raffaele Scientific Institute, Milan, Italy and the… Read More »
DBE-T may be a valid therapeutic target for FSHD
Past FSH Society fellows publish research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD”
Past FSH Society fellows publish research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD” in Epigenetics that proposes a prognostic marker that can… Read More »
Choice of transcriptional direction from each D4Z4 unit is an additional requirement for DUX4 production and having FSHD
FSHD research teams in Seattle, Rochester and Leiden add to the existing FSHD model loss of heterochromatin at D4Z4 and the presence of a specific haplotype on chromosome 4 are… Read More »
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy”
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy” in The American Society of Gene & Cell Therapy providing proof-of-principle… Read More »
New paper in Developmental Cell
New paper in Developmental Cell identifies a set of genes regulated by DUX4 and suggests possible mechanisms for causing muscle damage that might be targeted for developing therapies “DUX4 Activates … Read More »